Hemolytic Anemia Cell Models for Research

Hemolytic anemia is a condition characterized by premature destruction of red blood cells (RBCs), leading to anemia. The global burden is significant, with inherited forms such as sickle cell disease (SCD) and thalassemia affecting millions worldwide. According to the World Health Organization (WHO), approximately 5% of the world's population carries a trait for hemoglobin disorders, and over 300,000 babies are born with severe forms each year. Acquired hemolytic anemias, including autoimmune hemolytic anemia (AIHA), also contribute to morbidity. The clinical impact includes fatigue, jaundice, splenomegaly, and complications like gallstones and pulmonary hypertension. The 5-year survival varies by subtype; for example, SCD has a median survival of about 40-60 years in high-income countries, but much lower in resource-limited settings (NCI).

Hemolytic anemia is an ideal model for studying RBC biology, membrane stability, and enzyme function. The disease encompasses a wide range of genetic defects, providing a rich landscape for mechanistic studies. Public datasets, such as those from the Human Gene Mutation Database (HGMD) and ClinVar, offer extensive variant information. Open questions include the molecular basis of disease severity variation, the role of oxidative stress, and the development of targeted therapies. Gene-edited cell models enable precise manipulation of disease-associated genes, facilitating functional studies and drug development.

While hemolytic anemia is not a cancer, the underlying pathways involve RBC membrane integrity, hemoglobin stability, and metabolic enzymes. Key pathways include:

• • RBC Membrane Skeleton Pathway: Defects in spectrin, ankyrin, or band 3 lead to membrane fragility, as seen in hereditary spherocytosis.
• • Hemoglobin Oxygen Transport Pathway: Mutations in globin genes (e.g., HBB) cause sickle cell disease or thalassemia, leading to RBC sickling or ineffective erythropoiesis.
• • Pentose Phosphate Pathway (PPP): Glucose-6-phosphate dehydrogenase (G6PD) deficiency impairs NADPH production, increasing oxidative stress and hemolysis.
• • Glycolytic Pathway: Pyruvate kinase (PKLR) deficiency reduces ATP production, leading to RBC rigidity and hemolysis.

Data from TCGA, COSMIC, and ClinVar.

Hemolytic anemia involves several signaling networks:

• • Oxidative Stress Response: NRF2/KEAP1 pathway is critical in G6PD deficiency; oxidative damage leads to hemolysis.
• • Erythropoiesis Regulation: JAK2/STAT5 and PI3K/AKT pathways are involved in RBC production; defects can lead to ineffective erythropoiesis.
• • Apoptosis and Cell Survival: BCL2 family members regulate RBC lifespan; imbalances contribute to hemolysis.
• • Complement System: In paroxysmal nocturnal hemoglobinuria (PNH), complement-mediated lysis occurs due to GPI anchor deficiency.

Organoids derived from hematopoietic stem cells (HSPCs) can recapitulate erythropoiesis and are useful for studying hemolytic anemia. They allow 3D culture and can be gene-edited.

Animal models for hemolytic anemia include:

• • Sickle Cell Mouse Models: Berkeley (sickle) mouse, Townes mouse, and humanized SCD mice.
• • Thalassemia Models: β-thalassemic mice (Hbbth1/th1) and α-thalassemic mice.
• • G6PD-Deficient Models: G6PD mutant mice (e.g., G6PDx) with induced hemolysis.
• • Pyruvate Kinase Deficiency Models: PKLR knockout mice.
• • Hereditary Spherocytosis Models: Sptb knockout mice.

These models are used for studying pathophysiology and testing therapies.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations. For hemolytic anemia, key models include:

• • PKLR Knockout Cell Lines: Generated in erythroid cell lines (e.g., K562) to study pyruvate kinase deficiency.
• • G6PD Mutant Cell Lines: Introduction of common mutations (e.g., G202A) to model enzyme deficiency.
• • HBB Knock-In Lines: Introduction of sickle mutation (Glu6Val) in HUDEP-2 cells to model SCD.
• • SPTB Knockout Lines: To study hereditary spherocytosis.

These models are commercially available and sequence-verified, accelerating research. They are used for drug screening, functional studies, and target validation.

Gene-edited cell lines are essential for functional genomics. For example:

• • PKLR Knockout in K562 cells can be used to assess the impact on ATP levels and cell viability.
• • G6PD Knockout in HUDEP-2 cells can be used to study oxidative stress response.
• • HBB Knock-In lines enable the study of sickling under hypoxic conditions.

These models allow researchers to validate gene function and identify modifier genes.

Isogenic pairs (wild-type vs. mutant) are powerful for drug screening. For example:

• • Sickle Cell Disease Models: Used to test drugs that inhibit hemoglobin polymerization (e.g., voxelotor).
• • G6PD Deficiency Models: Used to screen for antioxidants that protect against hemolysis.
• • Pyruvate Kinase Deficiency Models: Used to test small molecules that activate pyruvate kinase (e.g., mitapivat).

These screens can identify compounds that specifically target the mutant phenotype.

CRISPR synthetic lethality screens can identify novel therapeutic targets. For example:

• • In G6PD-deficient cells, screening for genes that become essential when G6PD is knocked out can reveal new drug targets.
• • In PKLR-deficient cells, synthetic lethal partners may include genes in the glycolytic pathway.

These approaches can lead to the discovery of biomarkers for patient stratification.